JP2022506891A - Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 - Google Patents

Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 Download PDF

Info

Publication number
JP2022506891A
JP2022506891A JP2021525000A JP2021525000A JP2022506891A JP 2022506891 A JP2022506891 A JP 2022506891A JP 2021525000 A JP2021525000 A JP 2021525000A JP 2021525000 A JP2021525000 A JP 2021525000A JP 2022506891 A JP2022506891 A JP 2022506891A
Authority
JP
Japan
Prior art keywords
alkyl
compound according
aryl
hydroxy
optionally substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021525000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022506891A5 (enExample
Inventor
ゴッシュ，ショミア
カッツ，ジェイソン
ロウシュ，ウィリアム
セイデル，ハンズ，マーティン
シェン，ドン－ミン
ヴェンカトラマン，シャンカー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2022506891A publication Critical patent/JP2022506891A/ja
Publication of JP2022506891A5 publication Critical patent/JP2022506891A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021525000A 2018-11-13 2019-11-11 Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物 Pending JP2022506891A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862760244P 2018-11-13 2018-11-13
US201862760195P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US62/760,195 2018-11-13
US62/760,244 2018-11-13
US62/760,248 2018-11-13
PCT/US2019/060772 WO2020102098A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (2)

Publication Number Publication Date
JP2022506891A true JP2022506891A (ja) 2022-01-17
JP2022506891A5 JP2022506891A5 (enExample) 2022-11-21

Family

ID=68916530

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021525000A Pending JP2022506891A (ja) 2018-11-13 2019-11-11 Ｎｌｒｐ活性に関連する状態を処置するための化合物及び組成物

Country Status (6)

Country Link
US (1) US12421223B2 (enExample)
EP (1) EP3880673B1 (enExample)
JP (1) JP2022506891A (enExample)
CN (1) CN113015730A (enExample)
ES (1) ES2974842T3 (enExample)
WO (1) WO2020102098A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3649112A1 (en) * 2017-07-07 2020-05-13 Inflazome Limited Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
US20250243172A1 (en) * 2022-04-21 2025-07-31 Virginia Commonwealth University Nlrp3 inflammasome inhibitors and compositions and uses thereof
TW202545527A (zh) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Ｎｌｒｐ３及ｇｌｐ－１ａ組合療法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA2065346C (en) 1989-09-05 2005-03-29 Craig A. Smith Tumor necrosis factor-.alpha. and-.beta. receptors
CA2085297A1 (en) 1991-12-20 1993-06-21 James Edward Ray Sulfonimidamides
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
PL344004A1 (en) * 1998-05-05 2001-09-10 Hoffmann La Roche Pyrazole derivatives as p-38 map kinase inhibitors
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
US20080280910A1 (en) * 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
US9701689B2 (en) 2012-11-30 2017-07-11 Kyowa Hakko Kirin Co., Ltd. Substituted pyridines and pyridazines as CCR10 receptor inhibitors
ITMI20131658A1 (it) 2013-10-08 2015-04-09 Getters Spa Combinazione di materiali per dispositivi di rilascio di mercurio e dispositivi contenenti detta combinazione di materiali
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
JP6929792B2 (ja) * 2015-02-16 2021-09-01 ザ ユニバーシティ オブ クィーンズランド スルホニル尿素及び関連化合物並びにその使用
BR112018008506B8 (pt) * 2015-10-29 2023-12-05 Merck Sharp & Dohme Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
FR3046933B1 (fr) * 2016-01-25 2018-03-02 Galderma Research & Development Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires
US11447460B2 (en) * 2016-04-18 2022-09-20 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
MA44729A (fr) * 2016-04-18 2021-05-12 Novartis Ag Composés et compositions pour traiter des états associés à une activité de nlrp
EP3445761A1 (en) 2016-04-19 2019-02-27 Innate Tumor Immunity, Inc. Nlrp3 modulators
KR102521955B1 (ko) * 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
UA126675C2 (uk) 2017-01-23 2023-01-11 Дженентек, Інк. Хімічні сполуки як інгібітори активності інтерлейкіну-1
EP3634951B8 (en) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Novel substituted sulfoximine compounds
JP7412328B2 (ja) 2017-07-24 2024-01-12 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
WO2019034697A1 (en) 2017-08-15 2019-02-21 Inflazome Limited NOVEL CARBOXAMIDE SULFONAMIDE COMPOUNDS
MA53172A (fr) 2018-07-20 2021-05-26 Hoffmann La Roche Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1
GB201902327D0 (en) 2019-02-20 2019-04-03 Inflazome Ltd Novel compounds
PY1975819A (es) 2018-09-13 2020-04-09 Bayer Ag Derivados heterocíclicos como plaguicidas.-
WO2020150674A1 (en) 2019-01-18 2020-07-23 Nuvation Bio Inc. Heterocyclic compounds as adenosine antagonists
CN114008030A (zh) 2019-06-21 2022-02-01 Ac免疫有限公司 用作nlrp3调节剂的稠合的1,2-噻唑和1,2-噻嗪

Also Published As

Publication number Publication date
WO2020102098A1 (en) 2020-05-22
EP3880673A1 (en) 2021-09-22
US12421223B2 (en) 2025-09-23
CN113015730A (zh) 2021-06-22
EP3880673B1 (en) 2024-01-03
US20230025630A1 (en) 2023-01-26
ES2974842T3 (es) 2024-07-01

Similar Documents

Publication Publication Date Title
JP7654767B2 (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
CN111094242B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
CN113166065B (zh) 用于治疗与nlrp活性相关的病症的化合物和组合物
JP2022505525A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
JP2021529187A (ja) Ｎｌｒｐモジュレータ
JP2020537657A (ja) Ｎｌｒｐ活性に関連する病態を治療するためのスルホンアミド及びその組成物
US12134611B2 (en) Compounds and compositions for treating conditions associated with NLRP activity
JP2022507506A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
JP2022518260A (ja) Ｎｌｒｐ活性に関連する状態を治療するためのスルホンイミドアミド化合物及び組成物
US20220227707A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
US20220387397A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
JP2021529186A (ja) Ｎｌｒｐ調節剤
EP3880673B1 (en) Compounds and compositions for treating conditions associated with nlrp activity
JP2022507505A (ja) Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
JP2021534158A (ja) イミダゾ［４，５−ｃ］キノリン誘導体のＮＬＲＰ３モジュレーター

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221111

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230822

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240319